Introduction {#s0005}
============

In pulmonary arterial hypertension (PAH), increases in endothelin-1 (ET-1) contribute to elevated pulmonary vascular resistance which ultimately causes death by right ventricular heart failure. PAH involves injury to the pulmonary vasculature producing elevations in pulmonary arterial pressure. As PAH progresses, chronic pressure and volume overload cause alteration of the structure of the right ventricle (RV) including hypertrophy and dilatation. As a result, the space taken up by the RV in the pericardium increases, impeding left ventricular (LV) diastolic filling, reducing LV end-diastolic volume and altering the LV contractile function ([@bb0010]). Right heart failure is the major cause of death in PAH patients. ET antagonists are effective in treating PAH ([@bb0070]) but in marked contrast, lack efficacy in treating left ventricular heart failure ([@bb0045; @bb0050]). This is surprising as the density of ET~A~ receptors in the LV of patients with ischaemic heart disease is significantly increased by 50%, compared with non-failing hearts ([@bb0100]). However measurement of receptor density in the RV from patients with PAH using radioligand binding assays has not been studied.

ET~A~ receptors are the principal sub-type in the medial or smooth muscle layer of human blood vessels, including large epicardial and small resistance coronary arteries within the heart where ET~A~ receptors mediate vasoconstriction ([@bb0095; @bb0110]). We have previously shown that in human large conduit vessels these are altered in cardiovascular disease including PAH ([@bb0060]). [@bb0015] found no change in ratio of ET~A~:ET~B~ but increased overall receptor density in smooth muscle cells from human pulmonary small resistance arteries in PAH.

ET~B~ receptors localise to the endothelium and cause beneficial vasodilatation by the release of endothelium derived relaxing factors, opposing constrictor tone. In addition, in organs such as the lungs that are rich in ET~B~ receptors ([@bb0005]), this sub-type functions to clear ET-1 from the plasma ([@bb0040]). Two classes of ET antagonist are used clinically, mixed antagonists that block both sub-types and ET~A~ selective drugs. The precise molecular mechanism whereby these antagonists produce benefit in PAH is not established. In particular, the contribution of ET~B~ receptors to the development of this condition and the need to block this sub-type as well as the ET~A~ is still unclear ([@bb0140]). Our aim was to compare the density of both ET receptor sub-types in surgical samples from the right and LV of hearts and lungs removed from PAH patients at the time of transplantation, in comparison with normal tissues. Secondly to measure receptor density in a widely use animal model of PAH, which recapitulates a majority of the features of the human condition including right ventricular failure ([@bb0120]).

Materials and methods {#s0010}
=====================

Human heart {#s0030}
-----------

Surgical samples of LV and RV were obtained from PAH patients (idiopathic pulmonary artery hypertension) undergoing heart--lung transplantation and from normal controls that were not suitable for transplantation. Samples of PAH lung were obtained from patients undergoing lung transplantation and histologically normal control tissue was from patients undergoing lung lobectomy procedures. All tissues were collected with informed consent and ethical approval.

MCT-rat tissue collection {#s0035}
-------------------------

The procedures used in this study were approved by the local animal ethical committee and were performed under UK Home Office Project Licence authority; the study conformed to the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals. Male Sprague--Dawley rats (approximately 250 g) received a single subcutaneous injection of monocrotaline (60 mg/kg) at day 0 to induce PAH ([@bb0075]). The rats were maintained for three weeks following injection to develop muscularization of small pulmonary arteries in the lungs and right ventricular hypertrophy but without developing dilated heart failure ([@bb0075]). Rats were euthanized by CO~2~ inhalation. Organs were removed and snap-frozen in liquid nitrogen and stored at − 70 °C until further use.

Competition assays {#s0040}
------------------

Cryostat-cut tissue sections (10 μm) were mounted onto gelatine coated microscope slides.

Competition binding assays were performed as previously described ([@bb0080]), to determine the affinities (K~D~) and maximum densities (B~MAX~) of ET~A~ and ET~B~ receptors.

Sections were incubated with 0.1 nM \[^125^I\]-ET-1 (Perkin Elmer) and increasing concentrations (20 pM--10 μM) of the ET~A~ selective agonist FR139317 for 2 h at 23 °C. Non-specific binding (NSB) was determined using 1 μM of unlabelled ET-1. Following incubation and washing (3 × 5 min) in ice-cold Tris--HCl buffer to break the equilibrium, sections were counted in a gamma counter.

Competition curves were obtained by plotting specific binding as a percentage of total binding (binding in the absence of competitor) against the log concentration of the competing ligand. The data were analysed (see [@bb0085]) using non-linear iterative curve fitting programmes (KELL, containing EBDA and LIGAND programmes, Biosoft, Cambridge UK) to calculate K~D~ (affinity constant) and B~MAX~ (maximum density of receptors).

Autoradiography {#s0045}
---------------

For autoradiographical analysis, binding was carried as previously described ([@bb0065]) using assay conditions outlined above in a set of adjacent sections, to determine total \[^125^I\]-ET-1 (0.1 nM) binding, non-specific binding (1 μM unlabelled ET-1) and with selective antagonists, either 0.1 μM BQ3020 or 0.1 μM FR139317 to determine ET~A~ and ET~B~ receptor distribution respectively. Adjacent sections were stained to facilitate histological identification of pulmonary vasculature. Sections were washed to break the equilibrium and apposed, together with calibrated radioactive standards, to radiation-sensitive film (Kodak BioMax MR-1, Perkin Elmer). Resulting autoradiograms were analysed by measuring diffuse integrated optical density using the Quantimet 970 image analysis system. ET-1 receptor density was measured by digitizing each autoradiographical image and regions of interest on tissue sections were delineated. Optical densities were converted to specifically bound radioligand by interpolation from standard curves and subtraction of non-specific binding in an adjacent section.

Results {#s0015}
=======

Pharmacodynamic parameters in human and rat heart {#s0050}
-------------------------------------------------

In human normal hearts, competition binding revealed the expected ratio of ET~A~ to ET~B~ receptors ([Fig. 1](#f0015){ref-type="fig"}A, [@bb0100]). FR139317 competed biphasically for the binding of \[^125^I\]-ET-1, with a two-site fit preferred over a one-site model with no significant difference in affinity constants ([Table 1](#t0005){ref-type="table"}, K~D~) between patient groups ([Fig. 1](#f0015){ref-type="fig"}). Whilst there was no significant change in receptor sub-type ratio in LV, there is a significant increase in ET~A~ with a concomitant decrease in ET~B~ receptors in the failing RV ([Fig. 1](#f0015){ref-type="fig"}B, C).

In the rat model ([Fig. 1](#f0015){ref-type="fig"}D) the expected ratio of receptor sub-types was observed in both chambers of the hearts of control rats ([@bb0105]). In the MCT rat, receptor density was significantly different in the RV compared with vehicle control but with ET~A~ downregulation and ET~B~ upregulation ([Fig. 1](#f0015){ref-type="fig"}E, F). These changes led to a significant shift in relative ET~A~:ET~B~ receptor density ratio from 73:27 in control rat RV to 51:49 in MCT-rat RV. In the LV, no significant difference in ET~A~ and ET~B~ receptor density in MCT-rat heart compared to controls was observed ([Table 2](#t0010){ref-type="table"}).

Pharmacodynamic parameters in human PAH and MCT lung {#s0055}
----------------------------------------------------

Competition studies using whole cryostat sections in the lungs from patients with PAH compared to normal control tissues did not detect a significant difference in binding affinities (K~D~) for ET~A~ or ET~B~ and no change in receptor densities (B~MAX~) or ratio of sub-types in human PAH lungs compared with control ([Fig. 2](#f0005){ref-type="fig"}B, [Table 3](#t0015){ref-type="table"}). In agreement, there were no changes in these parameters in MCT lungs compared with control. However, following apposition of labelled sections to radiation sensitive film, image analysis permitted the measurement of densities in discrete cell types. In the medial layer of small pulmonary arteries identified by comparison with adjacent stained sections, there was a significant increase in vascular ET~A~ receptors in PAH compared with control small vessels ([Fig. 3](#f0010){ref-type="fig"}A, [Table 3](#t0015){ref-type="table"}). No equivalent changes were detected in the medial layer of MCT rat lungs compared with control ([Fig. 3](#f0010){ref-type="fig"}B, [Table 3](#t0015){ref-type="table"}).

Discussion {#s0020}
==========

Human heart with PAH {#s0060}
--------------------

We have previously shown that ET~A~ receptors in the failing LV of patients with ischaemic heart disease are significantly increased by 50% ([@bb0100; @bb0105]). In agreement, in the failing RV of patients with PAH, there was a significant increase in the ratio of ET~A~ receptors in ET~B~ density. In agreement, [@bb0115] using semi-quantitative immunocytochemistry also found an increase in ET~A~ expression in RV of patients with PAH. It is well established that levels of ET-1 are higher in PAH patients ([@bb0135]). In addition, in animal models, clearance and internalization of ET-1 by ET~B~ receptors are critical in preventing circulating ET-1 from binding to ET~A~ receptors in the heart ([@bb0040]) and the reduction that we observed in the RV in ET~B~ could contribute further to tissue levels. Taken together, these results suggest the potential for increased inotropic action via the ET~A~ sub-type. The RV of PAH patients is subjected to both pressure overload and autocrine/paracrine mediators such as ET-1, whereas the LV is only subjected to the latter. The RV and LV also have different embryological origins ([@bb0025]) and may respond differently to stressors and to therapies.

In PAH, the main benefit of ET antagonists may block deleterious vascular effects rather than improve cardiac function. In support of this hypothesis, in this study we have been able to determine, using autoradiography, the ET receptor densities within the smaller vessels of the tertiary structures of the lung demonstrating, in agreement with [@bb0015], a ratio 50:50 for ET~A~ to ET~B~ receptors with a significant increase in the ET~A~ subtype in PAH vessels compared to control lung vessels. There was no change in ET~B~ receptors, consistent with results in other human diseased vessels ([@bb0090]).

Modulation of ET receptors in the RV of PAH patients suggests an adaptive response to both the pressure overload and changes in autocrine/paracrine mediators, such as ET-1, experienced by these patients. In heart failure, increased receptor density may be an adaptive response to increase beneficial cardiac contractility. ET receptor antagonists may therefore decrease RV function. In a clinical trial comparing bosentan, a mixed ET antagonist with sidenafil, both decreased pulmonary arterial pressure to the same extent but unlike sildenafil, bosentan failed to improve RV ejection ([@bb0145]).

Rat model of PAH {#s0065}
----------------

In agreement with human PAH, there was no change in ET receptor density in the LV but ET receptor density was changed in the RV in the MCT rat, albeit the ratio was reversed compared with human. In addition, we did not detect an equivalent increase in receptor density in the medial layer of small arteries in MCT rat lungs. This may be because although MCT-treated rats develop PAH with marked RV hypertrophy, MCT causes these changes within three weeks, whereas patients undergoing transplantation of heart and lungs are in the later stages of the disease. There is a consensus in the rat model of pulmonary hypertension that neither RV systolic pressure nor function is improved in this model by the mixed receptor antagonist, bosentan (see for example, [@bb0030; @bb0035]). Interestingly, selective ET~A~ antagonists have demonstrated efficacy in this model ([@bb0125; @bb0055]).

Conclusion {#s0025}
==========

The main finding in this study is that there was a significant increase in the ratio of ET~A~ to ET~B~ in the RV from human PAH hearts compared with control, implying that this could translate into an increase in inotropic action by ET, particularly as levels of the peptide also elevated in PAH. Currently, ET~A~ and mixed ET~A~/ET~B~ receptor antagonists are both effective in the treatment of PAH. Both would be expected to block any increased inotropic action mediated by ET, suggesting that the inotropic effect is not a major benefit in the RV of PAH patients where the RV is characterised by hypertrophy. ET~A~ receptors also increase in the LV of patients with heart failure but in marked contrast to PAH, ET receptor antagonists have not fulfilled their expected promise in clinical trials; beneficial positive inotropic actions of ET may be more important in cardiomyopathy. Thus whilst ET antagonists in left ventricular heart failure produce the desired vasodilatation, this is offset by fluid retention and activation of the renin hypertension system. In PAH, ET antagonists effectively cause the desired pulmonary vasodilatation whereas blocking cardiac ET receptors has little impact on clinical worsening.

PAH is characterized by high pulmonary vascular resistance and vascular remodelling, which results in RV afterload and subsequent failure. Current treatments for PAH including ET antagonists have tended to focus on pulmonary vasodilatation. This study has confirmed the upregulation of ET~A~ receptors in the pulmonary vasculature of PAH patients where the known vasodilator properties of ET antagonists are of benefit. Crucially, the study has also provided evidence for an increase in the ratio of ET~A~ receptors in the RV, implying changes to the ET signalling pathway but it is unclear whether ET antagonism is beneficial. These results emphasise the still unexploited potential for therapies that target the RV, with the aim of supporting the RV of the heart, to improve survival in patients with PAH ([@bb0130]).
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![A--C Competition of FR139317 for \[^125^I\]-ET-1 binding in human left (LV) and right (RV) ventricles from (A) normal controls and (B) patients transplanted for PAH. A biphasic curve was obtained as expected in each case corresponding to a high affinity ET~A~ and low affinity ET~B~ site, allowing the affinities (K~D~), densities (B~MAX~) and ratio of the two sub-types to be measured. (C) Comparison of ET sub-type ratio in LV and RV in hearts from normal controls and patients with PAH showing a significant increase in ET~A~ but decrease in ET~B~ in the right ventricle (n = 12 PAH and 9 control individuals, mean ± s.e.mean; Student\'s t-test, \*p \< 0.05 t-test).](gr1){#f0015}

![Competition of FR139317 for \[^125^I\]-ET-1 binding to human lung from (A) normal controls and patients transplanted for PAH. A biphasic curve was obtained as expected in each case corresponding to a high affinity ET~A~ and low affinity ET~B~ site (B) Comparison of ET sub-type ratio in the lungs from normal controls and patients with PAH showing no significant change in the ratio of either sub-type (n = 8 PAH and 7 control individuals, mean ± s.e.mean). (C) Competition of FR139317 for \[^125^I\]-ET-1 binding in rat lung controls and MCT rats. A biphasic curve was also obtained as expected in each case corresponding to a high affinity ET~A~ and low affinity ET~B~ site. (D) Comparison of ET sub-type ratio in the lungs of control and MCT treated rats, control and patients MCT arts with PAH showing no significant change in the ratio of either sub-type (n = 5 MCT and 3 control rats ± s.e.mean).](gr2){#f0005}

![Autoradiographical analysis of the density (amol/mm^2^) in the binding of \[^125^I\]-ET-1 to ET~A~ and ET~B~ to the smooth muscle (medial) of small pulmonary arteries from PAH compared to normal control lung tissues showing. There was a significant increase in ET~A~ compared with normal vessels (A) but no change in ET~B~ (n = 8 PAH and 7 control individuals ± s.e.mean; \*p \< 0.05 t-test). In the lungs of MCT rats (B), there was no change (n = 6 MCT and 6 control rats ± s.e.mean).](gr3){#f0010}

###### 

K~D~ (affinity constant) and B~MAX~ (maximum density of receptors) values for ET~A~ and ET~B~ receptor subtypes human left and right ventricles from normal controls and patients transplanted for PAH.

  Human heart       ET~A~ K~D~ (nM)   ET~A~ B~MAX~ (fmol/mg)   ET~B~ K~D~ (μM)   ET~B~ B~MAX~ (fmol/mg)   Ratio % ET~A~:ET~B~                                                       
  ----------------- ----------------- ------------------------ ----------------- ------------------------ ------------------------------------------------------------------------- -------
  Normal (n = 12)   LV                0.60 ± 0.01              66.1 ± 4.2        44.9 ± 3.2               44.6 ± 8.5                                                                64:36
  RV                0.41 ± 0.11       69.2 ± 5.1               28.7 ± 1.9        75.7 ± 18.1              52:48                                                                     
  PAH (n = 9)       LV                0.76 ± 0.25              85.3 ± 11.4       36.2 ± 4.9               38.3 ± 6.4                                                                69:31
  RV                0.45 ± 0.08       80.8 ± 7.8               36.5 ± 2.9        37.0 ± 5.5               [⁎](#tf0005){ref-type="table-fn"}69:[⁎](#tf0005){ref-type="table-fn"}31   

n = 12/9 individuals, mean ± s.e.mean.

p \< 0.05 t-test.

###### 

Comparison of ET sub-type ratio in LV and RV in hearts from normal control rats and MCT rats with PAH.

  Rat heart                       ET~A~ K~D~ (nM)   ET~A~ B~MAX~ (fmol/mg)   ET~B~ K~D~ (μM)   ET~B~ B~MAX~ (fmol/mg)                                                        Ratio % ET~A~:ET~B~
  ----------------- ------------- ----------------- ------------------------ ----------------- ----------------------------------------------------------------------------- ---------------------
  Control (n = 6)   LV            1.10 ± 0.29       194.0 ± 24.9             49.4 ± 8.99       80.3 ± 13.2                                                                   70.3:29.7
  RV                0.77 ± 0.18   346.7 ± 42.8      28.7 ± 7.53              89.0 ± 16.3       73.4:26.6                                                                     
  MCT (n = 6)       LV            0.66 ± 0.11       167.9 ± 22.7             56.7 ± 2.02       94.1 ± 9.30                                                                   63.1:36.9
  RV                0.79 ± 0.07   147.4 ± 20.0      47.3 ± 7.85              139.7 ± 14.8      [⁎](#tf0010){ref-type="table-fn"}51.1:[⁎](#tf0010){ref-type="table-fn"}48.9   

n = 5 individuals ± s.e.mean.

p \< 0.05 t-test.

###### 

K~D~ (affinity constant) and B~MAX~ (maximum density of receptors) values for ET~A~ and ET~B~ receptor subtypes in human lung from normal controls and patients transplanted for PAH (n = 12 and 8 individuals) and rat lungs from control and monocrotaline treated animals (n = 3 and 5 animals), data are mean ± s.e.mean, No significant difference from control values (Student\'s t-test) at p \< 0.05 was detected.

                ET~A~ K~D~ (nM)   ET~A~ B~MAX~ (fmol/mg)   ET~B~ K~D~ (μM)   ET~B~ B~MAX~ (fmol/mg)   Ratio % ET~A~:ET~B~   
  ------------- ----------------- ------------------------ ----------------- ------------------------ --------------------- -------
  Human         Normal (n = 7)    2.05 ± 1.09              128.5 ± 19.0      13.4 ± 0.81              257.5 ± 48.0          34:66
  PAH (n = 8)   1.67 ± 2.49       137.0 ± 38.6             13.8 ± 1.11       181.0 ± 30.3             36:64                 
  Rat           Control (n = 3)   5.24 ± 7.40              63.4 ± 25.8       55.9 ± 9.45              125.8 ± 34.6          31:69
  MCT (n = 5)   0.58 ± 0.45       134.6 ± 57.0             63.5 ± 4.89       210.1 ± 50.1             36:64                 
